Статья
Нейротрофический фактор головного мозга в патогенезе коморбидности ишемической болезни сердца и депрессии: обзор
Ишемическая болезнь сердца (ИБС) и депрессия характеризуются высокой коморбидностью, имеющей двусторонний характер, однако ее патогенез практически не изучен.В последнее десятилетие стали изучаться нейрогенные механизмы воспалительной реакции и нейротрофический фактор головного мозга (от англ. brainderived neurotrophic factor, BDNF), который может объяснить связь между депрессией и ИБС. Обзор обобщает имеющуюся в литературе информацию, посвященную роли BDNF в патогенезе ИБС и депрессии, а также их коморбидного течения за период 2019-2024гг. На основании анализа литературы нами выделены компоненты и системы, наиболее перспективные для изучения роли BDNF в патогенезе данных мультифакториальных заболеваний (генетический компонент, воспаление, нейровоспаление, эндотелиальная дисфункция и чрезмерная активация тромбоцитов, гипоталамо-гипофизарнонадпочечниковая система, липопротеины низкой плотности и триглицериды). В обзоре подчеркивается важная роль BDNF в развитии депрессии при ИБС и необходимость проведения дальнейших исследований в этом направлении.
1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 392;1789-858. doi:10.1016/S0140-6736(18)32279-7.
2. Tschorn M, Rieckmann, N, Arolt, et al. Diagnostic accuracy of German depression screenings in patients with coronary heart disease. Psychiatrische Praxis. 2019;46(1): 41-8. doi:10.1055/s-0042-123434.
3. Baltramonaityte V, Pingault JB, Cecil CAM, et al. EarlyCause Consortium. A multivariate genome-wide association study of psycho-cardiometabolic multimorbidity. PLoS Genet. 2023;19(6). doi:10.1371/journal.pgen.1010508.
4. Wu Y, Zhu B, Chen Z, et al. New Insights Into the Comorbidity of Coronary Heart Disease and Depression. Curr Probl Cardiol. 2021;46(3):100413. doi:10.1016/j.cpcardiol.2019.03.002.
5. Cao H, Baranova A, Zhao Q, et al. Bidirectional associations between mental disorders, antidepressants and cardiovascular disease. BMJ Ment Health. 2024;27(1):e300975. doi:10.1136/bmjment-2023-300975.
6. Нагибина Ю.В., Кубарева М.И., Князева Д.С. Медико-социальные особенности больных ишемической болезнью сердца с различным уровнем депрессии. Кардиоваскулярная терапия и профилактика. 2019;18(6):142-51. doi:10.15829/1728-8800-2019-1930.
7. Нагибина Ю.В., Кубарева М.И., Князева Д.С. Гендерные особенности медико-социальных показателей больных ишемической болезнью сердца с различным уровнем депрессии. Кардиоваскулярная терапия и профилактика. 2021;20(1):2425. doi:10.15829/1728-8800-2021-2425.
8. Khandaker GM, Zuber V, Rees JMB, et al. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. Mol Psychiatry. 2020;25(7):1477-86. doi:10.1038/s41380-019-0395-3.
9. Traub J, Schürmann P, Schmitt D, et al. Features of metabolic syndrome and inflammation independently affect left ventricular function early after first myocardial infarction. Int J Cardiol. 2023;370:43-50. doi:10.1016/j.ijcard.2022.10.142.
10. Xu L, Zhai X, Shi D, Zhang Y.Depression and coronary heart disease: mechanisms, interventions, and treatments. Front Psychiatry. 2024;15:1328048. doi:10.3389/fpsyt.2024.1328048.
11. Ferrari R, Pavasini R, Censi S, et al. The New ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes: the Good and the Not So Good. Curr Probl Cardiol. 2021;46(3):100554. doi:10.1016/j.cpcardiol.2020.100554.
12. Jurisch D, Laufs U.Chronic coronary syndrome: New classification of stable coronary artery disease. Internist (Berl). 2021;62(1):47-57. doi:10.1007/s00108-020-00910-0.
13. Chaturvedi S, De Marchis GM. Inflammatory Biomarkers and Stroke Subtype: An Important New Frontier. Neurology. 2024;102(2):208098. doi:10.1212/WNL.0000000000208098.
14. Christou GA, Andriopoulou CE, Liakopoulou A, et al. Unraveling the role of resistin, retinol-binding protein 4 and adiponectin produced by epicardial adipose tissue in cardiac structure and function: evidence of a paracrine effect. Hormones (Athens). 2023; 22(2):321-30. doi:10.1007/s42000-023-00447-5.
15. Атамась О.В., Антонюк М.В., Новгородцева Т.П. и др. BDNF/TrkB-сигналинг при стабильной ишемической болезни сердца. Российский кардиологический журнал. 2023;28(12):5535. doi:10.15829/1560-4071-2023-5535.
16. Halloway S, Jung M, Yeh AY, et al. An Integrative Review of Brain-Derived Neurotrophic Factor and Serious Cardiovascular Conditions. Nurs Res. 2020;69(5):376-90. doi:10.1097/NNR.0000000000000454.
17. Hang PZ, Zhu H, Li PF, et al. The Emerging Role of BDNF/TrkB Signaling in Cardiovascular Diseases. Life (Basel). 2021;11(1):70. doi:10.3390/life11010070.
18. Sampogna G, Toni C, Catapano P, et al. New trends in personalized treatment of depression. Curr Opin Psychiatry. 2024;37(1):3-8. doi:10.1097/YCO.0000000000000903.
19. Perez-Caballero L, Torres-Sanchez S, Romero-López-Alberca C, et al. Monoaminergic system and depression. Cell Tissue Res. 2019;377(1):107-13. doi:10.1007/s00441-018-2978-8.
20. Menke A. The HPA Axis as Target for Depression. Curr Neuropharmacol. 2024;22(5): 904-15. doi:10.2174/1570159X21666230811141557.
21. Khandia R, Gurjar P, Kamal MA. Relative synonymous codon usage and codon pair analysis of depression associated genes. Sci Rep. 2024;14(1):3502. doi:10.1038/s41598-024-51909-8.
22. Chen HS, Wang F, Chen JG. Epigenetic mechanisms in depression: Implications for pathogenesis and treatment. Curr Opin Neurobiol. 2024;85:102854. doi:10.1016/j.conb.2024.102854.
23. Wei Y, Gao H, Luo Y. Systemic inflammation and oxidative stress markers in patients with unipolar and bipolar depression: A large-scale study. J Affect Disord. 2024;346:154-66. doi:10.1016/j.jad.2023.10.156.
24. Murawska-Ciałowicz E, Wiatr M, Ciałowicz M. BDNF Impact on Biological Markers of Depression-Role of Physical Exercise and Training. 2021;18(14):7553. doi:10.3390/ijerph18147553.
25. Буровенко И.Ю., Борщев Ю.Ю., Галагудза М.М. Нейро и кардиотропные эффекты мозгового нейротрофического фактора. University Therapeutic Journal. 2021; 3(4):83-102.
26. He T, Wu Z, Zhang X, et al. A Bibliometric Analysis of Research on the Role of BDNF in Depression and Treatment. Biomolecules. 2022;12(10):1464. doi:10.3390/biom12101464.
27. Wang Y, Cai X, Ma Y, et al. Metbolomics on depression: A comparison of clinical and animal research. J Affect Disord. 2024;349:559-68. doi:10.1016/j.jad.2024.01.053.
28. Hassan Almalki W. A study of abnormal cannabidiols system-mediated cardiovascular protection in disrupted gut/brain axis associated depression. J Biochem Mol Toxicol. 2021;35(12):e22930. doi:10.1002/jbt.22930.
29. Tschorn M, Kuhlmann SL, Rieckmann N, et al. Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease. Acta Neuropsychiatr. 2021;33(1):22-30. doi:10.1017/neu.2020.31.
30. Caruso G, Fresta CG, Grasso M, et al. Inflammation as the Common Biological Link Between Depression and Cardiovascular Diseases: Can Carnosine Exert a Protective Role? Curr Med Chem. 2020;27(11):1782-800. doi:10.2174/0929867326666190712091515.
31. Beurel E, Toups M, Nemeroff CB. The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron. 2020;107(2):234-56. doi:10.1016/j.neuron.2020.06.002.
32. Akosile W, Tiyatiye B, Colquhoun D, Young R. Management of depression in patients with coronary artery disease: A systematic review. Asian J Psychiatr. 2023;83:103534. doi:10.1016/j.ajp.2023.103534.
33. Kytikova O, Novgorodtseva T, Denisenko Y, et al. Brain-derived neurotrophic factor and coronary artery disease. Russian Open Medical Journal. 2022;11(2):202. doi:10.15275/rusomj.2022.0202.
34. Zietz A, Gorey S, Kelly PJ, et al. Targeting inflammation to reduce recurrent stroke. Int J Stroke. 2024;19(4):379-87. doi:10.1177/17474930231207777.
35. Troubat R, Barone P, Leman S, et al. Neuroinflammation and depression: A review. Eur J Neurosci. 2021;53(1):151-71. doi:10.1111/ejn.14720.
36. Wang M, Pan W, Xu Y, et al. Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases. J Inflamm Res. 2022;15:3083-94. doi:10.2147/JIR.S350109.
37. Шпак А.А., Гехт А.Б., Дружкова Т.А. и др. Нейротрофический фактор головного мозга и цилиарный нейротрофический фактор у пациентов с депрессией. Нейрохимия. 2020;37(2):188-92. doi:10.31857/S1027813320020119.
38. Вялова Н.М., Левчук Л.А. Роль BDNF в формировании депрессивных расстройств. Фундаментальные исследования. 2014;(10-4): 771-5.
39. Шепелева И.И., Чехонин И.В., Чернышева А.А. и др. Роль мозгового нейротрофического фактора в патогенезе депрессивных расстройств. Молекулярная медицина. 2021;19(3):8-16.
40. Osimo EF, Pillinger T, Rodriguez IM, et al. Inflammatory markers in depression: A metaanalysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901-9. doi:10.1016/j.bbi.2020.02.010.
41. Kojima M, Ishii C, Sano Y, et al. Journey of brain-derived neurotrophic factor: from intracellular trafficking to secretion. Cell Tissue Res. 2020;382(1):125-34. doi:10.1007/s00441-020-03274-x.
42. Sahay A, Kale A, Joshi S. Role of neurotrophins in pregnancy and offspring brain development. Neuropeptides. 2020;83:102075. doi:10.1016/j.npep.2020.102075.
43. Müller P, Duderstadt Y, Lessmann V, Müller NG. Lactate and BDNF: Key Mediators of Exercise Induced Neuroplasticity? J Clin Med. 2020;9(4):1136. doi:10.3390/jcm9041136.
44. Brigadski T, Leßmann V.The physiology of regulated BDNF release. Cell Tissue Res. 2020;382(1):15-45. doi:10.1007/s00441-020-03253-2.
45. Amadio P, Cosentino N, Eligini S, et al. Potential Relation between Plasma BDNF Levels and Human Coronary Plaque Morphology. Diagnostics (Basel). 2021;11(6):1010. doi:10.3390/diagnostics11061010.
46. Colucci-D'Amato L, Speranza L, Volpicelli, F.Neurotrophic Factor BDNF, Physiological Functions and Therapeutic Potential in Depression, Neurodegeneration and Brain Cancer. Int. J.Mol. Sci. 2020;21:7777. doi:10.3390/ijms21207777.
47. Britt RD Jr, Thompson MA, Wicher SA, et al. Smooth muscle brain-derived neurotrophic factor contributes to airway hyperreactivity in a mouse model of allergic asthma. FASEB J. 2019;33(2):3024-34. doi:10.1096/fj.201801002R.
48. László A, Lénárt L, Illésy L, et al. The role of neurotrophins in psychopathology and cardiovascular diseases: psychosomatic connections. J Neural Transm (Vienna). 2019; 126(3):265-78. doi:10.1007/s00702-019-01973-6.
49. Kermani P, Hempstead B. BDNF Actions in the Cardiovascular System: Roles in Development, Adulthood and Response to Injury. Front Physiol. 2019;10:455. doi:10.3389/ fphys.2019.00455.
50. Mauricio D, Castelblanco E, Alonso N. Cholesterol and Inflammation in Atherosclerosis: An Immune-Metabolic Hypothesis. Nutrients. 2020;12(8):2444. doi:10.3390/nu12082444.
51. Ruscica M, Corsini A, Ferri N, et al. Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacol. Res. 2020;159:104916. doi:10.1016/j.phrs.2020.104916.
52. Ruparelia N, Choudhury R. Inflammation and atherosclerosis: What is on the horizon? Heart. 2020;106:80-5. doi:10.1136/heartjnl-2018-314230.
53. Monisha KG, Prabu P, Chokkalingam M, et al. Clinical utility of brain-derived neurotrophic factor as a biomarker with left ventricular echocardiographic indices for potential diagnosis of coronary artery disease. Sci Rep. 2020;10(1):16359. doi:10.1038/s41598-020-73296-6.
54. Kim HW, Shi H, Winkler MA, et al. Perivascular Adipose Tissue and Vascular Perturbation/ Atherosclerosis. Arterioscler Thromb Vasc Biol. 2020;40(11):2569-76. doi:10.1161/ATVBAHA.120.312470.
55. Shafi O.Switching of vascular cells towards atherogenesis, and other factors contributing to atherosclerosis: a systematic review. Thromb J. 2020;18(1):28. doi:10.1186/s12959-020-00240-z.
56. Bi C, Fu Y, Zhang Z, et al. Prostaglandin E2 confers protection against diabetic coronary atherosclerosis by stimulating M2 macrophage polarization via the activation of the CREB/BDNF/TrkB signaling pathway. FASEB J. 2020;34(6):7360-71. doi:10.1096/fj.201902055R.
57. Zhao J, Du J, Pan Y. Activation of cardiac TrkB receptor by its small molecular agonist 7,8-dihydroxyflavone inhibits doxorubicin-induced cardiotoxicity via enhancing mitochondrial oxidative phosphorylation. Free Radic Biol Med. 2019;130:557-67. doi:10.1016/j.freeradbiomed.2018.11.024.
58. Lin B, Zhao H, Li L, et al. Sirt1 improves heart failure through modulating the NF-kappaB p65/microRNA-155/BNDF signaling cascade. Aging (Albany NY). 2020;12. doi:10.18632/aging.103640.
59. Bahls M, Könemann S, Markus MR, et al. Brain-derived neurotrophic factor is related with adverse cardiac remodeling and high NTproBNP. Scientific Reports. 2018;9(1):1-9. doi:10.1038/s41598-019-51776-8.
60. Kim JM, Stewart R, Kim JW, et al. Modifying effects of depression on the association between BDNF methylation and prognosis of acute coronary syndrome. Brain Behav Immun. 2019;81:422-9. doi:10.1016/j.bbi.2019.06.038.
61. Kotlega D, Zembron-Lacny A, Morawin B, et al. Free Fatty Acids and Their Inflammatory Derivatives Affect BDNF in Stroke Patients. Mediators Inflamm. 2020;2020:6676247. doi:10.1155/2020/6676247.
62. Rytter N, Carter H, Piil P, et al. Ischemic Preconditioning Improves Microvascular Endothelial Function in Remote Vasculature by Enhanced Prostacyclin Production. J Am Heart Assoc. 2020;9(15):e016017. doi:10.1161/JAHA.120.016017.
63. Schmalhofer ML, Markus MR, Gras JC, et al. Sex-Specific associations of brain-derived neurotrophic factor and cardiorespiratory fitness in the general population. Biomolecules. 2019;9(10):630. doi:10.3390/biom9100630.
64. Han M, Deng C. BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia. Neurosci Lett. 2020;726:133870. doi:10.1016/j.neulet.2018.10.015.
65. Notaras M, van den Buuse M.Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders. Mol. Psychiatry. 2020;25(10):2251-74. doi:10.1038/s41380-019-0639-2.
66. Liu YK, Gao H, Jin SB, et al. Association of neonatal blood levels of brain-derived neurotrophic factor with development of autism spectrum disorder: a systematic review and meta-analysis. World J Pediatr. 2021;17(2):164-70. doi:10.1007/s12519-021-00415-2.
67. Halloway S, Schoeny ME, Barnes LL, et al. A study protocol for MindMoves: A lifestyle physical activity and cognitive training intervention to prevent cognitive impairment in older women with cardiovascular disease. Contemp Clin Trials. 2021;101:106254. doi:10.1016/j.cct.2020.106254.
68. Wenceslau CV, de Souza DM, Mambelli-Lisboa NC, et al. Restoration of BDNF, DARPP32, and D2R Expression Following Intravenous Infusion of Human Immature Dental Pulp Stem Cells in Huntington's Disease 3-NP Rat Model. Cells. 2022;11:1664. doi:10.3390/cells11101664.
69. Kussainova A, Kassym L, Akhmetova A, et al. Associations between serum levels of brainderived neurotrophic factor, corticotropin releasing hormone and mental distress in vitiligo patients. Sci Rep. 2022;12(1):7260. doi:10.1038/s41598-022-11028-8.
70. Duman RS, Deyama S, Fogaça MV. Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants. Eur J Neurosci. 2021;53(1):126-39. doi:10.1111/ejn.14630.
71. Dvojkovic A, Nikolac Perkovic M, Sagud M, et al. Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2021;105:110016. doi:10.1016/j.pnpbp.2020.110016.
72. Tiwari S, Qi L, Wong J, et al. Association of peripheral manifestation of brain-derived neurotrophic factor with depression: A meta-analysis. Brain Behav. 2022;12(6):e32581. doi:10.1002/brb3.2581.
73. Brattico E, Bonetti L, Ferretti G, et al. Putting Cells in Motion: Advantages of Endogenous Boosting of BDNF Production. Cells. 2021;10(1):183. doi:10.3390/cells10010183.
74. Koyama S, Ito K, Terao C, et aI. Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. Nat Genet. 2021;52(11):1169-77. doi:10.1038/s41588-020-0705-3.
75. Li L, Chen Z, von Scheidt M, et al. Transcriptome-wide association study of coronary artery disease identifies novel susceptibility genes. Basic Res Cardiol. 2022;117(1):6. doi:10.1007/s00395-022-00917-8.
76. Christiansen MK, Nyegaard M, Jensen HK. Polygenic risk scores in coronary artery disease. Curr Opin Cardiol. 2023;38(1):39-46. doi:10.1097/HCO.0000000000001007.
77. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22(3):343-52. doi:10.1038/s41593-018-0326-7.
78. Hagenaars SP, Coleman JRI, Choi SW, et al. Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression. Am J Med Genet B Neuropsychiatr Genet. 2020;183(6):309-30. doi:10.1002/ajmg.b.32807.
79. Arosio B, Guerini FR, Voshaar RCO, Aprahamian I. Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective? Front Behav Neurosci. 2021. doi:10.3389/fnbeh.2021.626906:33643008.
80. Sandrini L, Castiglioni L, Amadio P, et al. Impact of BDNF Val66Met Polymorphism on Myocardial Infarction: Exploring the Macrophage Phenotype. Cells. 2020;9(5):1084. doi:10.3390/cells9051084.
81. Raucci FJ Jr, Singh AP, Soslow J, et al. The BDNF rs6265 Polymorphism is a Modifier of Cardiomyocyte Contractility and Dilated Cardiomyopathy. Int J Mol Sci. 2020;21(20): 7466. doi:10.3390/ijms21207466.
82. Kim OY, Song J. The importance of BDNF and RAGE in diabetes-induced dementia. Pharmacol Res. 2020;160:105083. doi:10.1016/j.phrs.2020.105083.
83. Canobbio I.Blood platelets: Circulating mirrors of neurons? Res Pract Thromb Haemost. 2019;3(4):564-5. doi:10.1002/rth2.12254.
84. Wei YG, Cai DB, Liu J. Cholesterol and triglyceride levels in first-episode patients with major depressive disorder: A meta-analysis of case-control studies. J Affect Disord. 2020;266:465-72. doi:10.1016/j.jad.2020.01.114.
85. Wu X, Qiu W, He H.Associations of the triglyceride-glucose index and remnant cholesterol with coronary artery disease: a retrospective study. Lipids Health Dis. 2024;23(1): 45. doi:10.1186/s12944-024-02036-w.
86. de Oliveira J, Moreira ELG, de Bem AF. Beyond cardiovascular risk: Implications of Familial hypercholesterolemia on cognition and brain function. Ageing Res Rev. 2024; 93:102149. doi:10.1016/j.arr.2023.102149.
87. Korade Z, Anderson A, Balog M, et al. Chronic Aripiprazole and Trazodone Polypharmacy Effects on Systemic and Brain Cholesterol Biosynthesis. Biomolecules. 2023; 13(9):1321. doi:10.3390/biom13091321.
88. Mulchandani R, Lyngdoh T, Nangia R, et al. Relationship between serum lipids and depression: A cross sectional survey among adults in Haryana, India. Indian J Psychiatry. 2023;65(1):61-7. doi:10.4103/indianjpsychiatry.indianjpsychiatry_967_21.
89. Cai L, Wei L, Yao J, et al. Impact of depression on the quality of sleep and immune functions in patients with coronary artery disease. Gen Psychiatr. 2022;35(6):e100918. doi:10.1136/gpsych-2022-100918.
90. Libby P.Inflammation and the pathogenesis of atherosclerosis. Vascul Pharmacol. 2024;154:107255. doi:10.1016/j.vph.2023.107255.
91. Neumann J, Hofmann B, Dhein S, et al. Cardiac Roles of Serotonin (5-HT) and 5-HT-Receptors in Health and Disease. Int J Mol Sci. 2023;24(5):4765. doi:10.3390/ijms24054765.
92. Tanaka M, Sackett S, Zhang Y. Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology. Front Neurol. 2020;11:87. doi:10.3389/fneur.2020.00087.
93. Deng SL, Chen JG, Wang F. Microglia: A Central Player in Depression. Curr Med Sci. 2020;40(3):391-400. doi:10.1007/s11596-020-2193-1.
94. Lu W, Wen J. Neuroinflammation and Post-Stroke Depression: Focus on the Microglia and Astrocytes. Aging Dis. 2024. doi:10.14336/AD.2024.0214-1.